8-K/A: XOMA Royalty Completes LAVA Acquisition, Details Legacy Assets

XOMA Royalty Corporation finalized its acquisition of LAVA Therapeutics, outlining the future of acquired legacy assets and contingent value rights.

Summary

• XOMA Royalty Corporation completed the acquisition of LAVA Therapeutics N.V. on November 20, 2025, following a tender offer.
• The acquisition included LAVA's legacy assets: EGFRd2 (PF-8046052), JNJ-89853413, and LAVA-1266.
• LAVA shareholders who did not tender shares will receive $1.04 cash and one Contingent Value Right (CVR) per share.
• EGFRd2, outlicensed to Pfizer, is in Phase 1 for non-small cell lung carcinoma and squamous cell carcinoma of head and neck, with potential future milestones up to approximately $650 million.
• JNJ-89853413, outlicensed to Janssen Biotech, is in Phase 1 for relapsed or refractory acute myeloid leukemia, with potential future milestones up to approximately $195 million.
• XOMA has no intention to develop LAVA-1266 and is pursuing its disposition.
• XOMA estimated the value of the CVRs at $0.00 due to the high uncertainty of early-stage oncology drug development and LAVA's prior assessment of LAVA-1266's limited market opportunity.
• XOMA will use commercially reasonable efforts for two years to dispose of the legacy assets and for ten years to maintain the Pfizer and JBI agreements, with 75% of net disposition proceeds going to CVR holders.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-slightly negative update. While the acquisition of potential royalty streams is strategically sound for XOMA, the explicit $0.00 valuation of the CVRs and the high uncertainty surrounding future milestone payments temper any immediate enthusiasm.

Positives

• Acquisition of two potentially high-value royalty streams (EGFRd2 and JNJ-89853413) with significant future milestone payment potential (up to $650 million and $195 million, respectively).
• XOMA's role is limited to potential receipt of payments, reducing direct development costs and risks for these two assets.
• The acquired assets are already partnered with major pharmaceutical companies (Pfizer and Janssen Biotech), indicating initial validation.

Negatives

• LAVA proactively waived a one-time buy-up option for increased royalties under the Pfizer Agreement for EGFRd2 prior to closing.
• XOMA has no intention to continue development of LAVA-1266 and is seeking its disposition, indicating a non-core or low-value asset.
• XOMA estimated the value of the Contingent Value Rights (CVRs) at $0.00, reflecting significant uncertainty regarding future payments from the legacy assets.
• The next milestone payment for EGFRd2 (low double digits millions) is contingent on completing the third part of a Phase 1 trial, which may not occur.
• The next milestone payment for JNJ-89853413 (mid-single digits millions) is contingent on dosing the fifth patient in a Phase 2 trial, which JBI may not proceed with.

Risks

• Significant uncertainty associated with early-stage development of pre-clinical therapies, where ultimate economic value depends on scientific, regulatory, commercial, temporal, and structural factors largely outside XOMA's control.
• Industry data indicates only a small fraction of oncology drug candidates progress from pre-clinical research to regulatory approval.
• Overall probability of approval for oncology drugs entering clinical development is estimated to be near-zero, with most candidates failing due to lack of efficacy, safety concerns, or commercial viability.
• Receipt of proceeds from the Pfizer and JBI Agreements is dependent on achieving specified clinical, regulatory, or commercial milestones that require successful advancement through multiple phases of human testing, regulatory approval, and minimum sales thresholds.
• Pfizer may decide not to proceed with the dose expansion part of the EGFRd2 Phase 1 trial, and XOMA would have no involvement.
• There is no guarantee that JBI will proceed with a Phase 2 clinical trial for JNJ-89853413, and XOMA would have no involvement.
• The future success of both EGFRd2 and JNJ-89853413 programs is subject to the uncertainty of clinical development, demonstration of efficacy, and decisions by Pfizer and JBI about which programs to advance within their portfolios, regardless of clinical trial results.
• Significant uncertainty exists regarding XOMA's ability to attract a potential acquirer for LAVA-1266, and even if an agreement is reached, whether the acquirer could successfully develop and commercialize it.

Future Outlook

The future outlook for the acquired legacy assets is highly uncertain. EGFRd2's Phase 1 trial is expected to complete in 2029 or 2030, and JNJ-89853413's Phase 1 trial is expected to complete in August 2028. Future milestone payments are contingent on successful clinical development, regulatory approvals, and commercialization, which are subject to significant risks and decisions by partner companies (Pfizer and JBI). XOMA has no intention to develop LAVA-1266 and is actively seeking its disposition.

Management Comments

• XOMA estimated the value of the proceeds that would be payable under the CVR Agreement at $0.00. Such estimate did not assign any value to EGFRd2 (PF-8046052) or JNJ-89853413 because of the significant uncertainty associated with early-stage development of pre-clinical therapies, where ultimate economic value depends on scientific, regulatory, commercial, temporal, and structural factors that are almost entirely outside the control of LAVA or XOMA.
• Such estimate, which also took into account LAVAs independent estimate, did not assign any value to LAVA-1266 because LAVA previously conducted an extensive business development process in an effort to out-license or otherwise dispose of LAVA-1266 and concluded that the market opportunity for LAVA-1266 is limited.

Industry Context

StockSavvy.ai notes that XOMA Royalty Corporation's acquisition of LAVA's legacy assets aligns with a strategy of acquiring royalty streams from early-stage biopharmaceutical programs. This approach allows XOMA to potentially benefit from future drug successes without incurring the substantial R&D costs and risks associated with direct drug development. However, the high-risk, high-reward nature of early-stage oncology assets, as highlighted by the low probability of approval and XOMA's $0.00 valuation of the CVRs, is a common characteristic in the biotech industry. The reliance on major pharmaceutical partners like Pfizer and Janssen Biotech for development and commercialization shifts operational burden but introduces dependence on their strategic portfolio decisions.

Comparison to Industry Standards

• The estimated near-zero overall probability of approval for oncology drugs entering clinical development, as cited in the filing, is consistent with widely accepted industry benchmarks. For example, a study by BIO, Biomedtracker, and Amplion found that the probability of success from Phase 1 to approval for oncology drugs is typically around 5-7%.
• The acquisition of royalty rights to early-stage assets, where the licensor (XOMA) has no further development involvement, is a standard model for royalty companies. This contrasts with integrated pharmaceutical companies like Pfizer or Janssen Biotech, which bear the full development risk and cost but retain full commercial rights.
• The decision to value the CVRs at $0.00 for early-stage oncology assets, particularly one (LAVA-1266) that previously failed to attract a partner, reflects a realistic assessment of the high attrition rates and market challenges inherent in this sector, aligning with conservative valuation practices for highly speculative assets.

Stakeholder Impact

• LAVA Shareholders: Will receive $1.04 cash per share and CVRs, the value of which XOMA estimates at $0.00, reflecting the high uncertainty of future payments from legacy assets.
• XOMA Shareholders: The acquisition adds potential future royalty streams, but also carries the inherent risks of early-stage drug development and the uncertainty of partner decisions, as reflected in the CVR valuation.
• Pfizer and Janssen Biotech: Continue their respective development programs for EGFRd2 and JNJ-89853413, with no change to their obligations or involvement.

Next Steps

• XOMA will use commercially reasonable efforts for two years after closing to enter into an agreement for the sale, transfer, license, or other disposition of EGFRd2, JNJ-89853413, or LAVA-1266.
• XOMA will use commercially reasonable efforts for ten years after closing to maintain and enforce the Pfizer Agreement and the JBI Agreement.
• LAVA's financial statements and pro forma financial information will be included in a future amendment to this Current Report on Form 8-K.
• Pfizer will continue the Phase 1 clinical trial for EGFRd2, expected to complete in 2029 or 2030.
• Janssen Biotech will continue the Phase 1 clinical trial for JNJ-89853413, expected to complete in August 2028.

Key Dates

Recommendation

The filing provides additional clarity on the acquired LAVA legacy assets and the CVRs, but it largely confirms the high-risk, long-term nature of these early-stage oncology royalty streams. XOMA's explicit $0.00 valuation of the CVRs, while conservative, underscores the significant uncertainty. Given that this is an amendment to a completed acquisition and the information aligns with expected risks in this sector, a seasoned investor would likely maintain a 'hold' position, awaiting further clinical development progress or definitive milestone achievements before adjusting their outlook.

Keywords

XOMA Royalty Corporation, LAVA Therapeutics, Acquisition, SEC Filing, 8-K/A, Contingent Value Rights, CVR, EGFRd2, PF-8046052, JNJ-89853413, LAVA-1266, Royalty Streams, Biotechnology, Pharmaceuticals, Clinical Trials, Oncology, Milestone Payments, Pfizer, Janssen Biotech, Asset Disposition